Trade Summary

1 month ago, Ra Capital Management, L.P., serving as Dir at Mineralys Therapeutics, Inc. (MLYS), purchased 369,000 shares at $23.75 per share, for a total transaction value of $8,762,797.00. Following this transaction, Ra Capital Management, L.P. now holds 7,692,750 shares of MLYS.

This purchase represents a 5.00% increase in Ra Capital Management, L.P.'s stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Friday, March 27, 2026 and publicly disclosed via SEC Form 4 filing on Tuesday, March 31, 2026 at 4:15 PM ET, 4 days after the trade was made.

Mineralys Therapeutics, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider buying activity in this sector can provide valuable signals about industry trends and company-specific developments.